Abstract
Background Mobile health offers potential benefits to patients and healthcare systems alike. Existing remote technologies to measure respiratory rate (RR) have limitations, such as cost, accessibility and reliability. Using smartphone sensors to measure RR may offer a potential solution.
Objective The aim of this study was to conduct a comprehensive assessment of a novel mHealth smartphone application designed to measure RR using movement sensors.
Methods In Study 1, 15 participants simultaneously measured their RR with the app, and an FDA cleared reference device. A novel reference method to allow the app to be evaluated ‘in the wild’ was also developed. In Study 2, 165 participants measured their RR using the app, and these measures were compared to the novel reference. Usability of the app was also assessed in both studies.
Results The app, when compared to the FDA-cleared and novel references, respectively, showed a mean absolute error (MAE) of 1.65 (SD=1.49) and 1.14 (1.44), relative MAE of 12.2 (9.23) and 9.5 (18.70) and bias of 0.81 (limits of agreement (LoA) =-3.27-4.89) and 0.08 (−3.68-3.51). Pearson correlation coefficients were 0.700 and 0.885. 93% of participants successfully operated the app on their first use.
Conclusions The accuracy and usability of the app demonstrated here show promise for the use of mHealth solutions employing smartphone sensors to remotely monitor RR. Further research should validate the benefits that this technology may offer patients and healthcare systems.
Competing Interest Statement
All authors are current or previous employees of Huma Therapeutics Ltd, which is the developer of the mHealth smartphone app. No additional conflicts of interest relevant to this study are declared.
Funding Statement
This study was funded by Huma Therapeutics Ltd.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval was provided by the University of Exeter's Research Ethics Board (application ID eUEBS004088) and all research was conducted in compliance with the Declaration of Helsinki.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding: This research was funded by Huma Therapeutics Ltd.
Conflict of Interest: SV, BK, MD, MB, DP, are or were employees of Huma Therapeutics Ltd at the time of writing.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
Abbreviations
- apps
- applications
- BPM
- breaths per minute
- FDA
- US Food and Drug Administration
- HCP
- healthcare professional
- LoA
- Limits of agreement
- MAE
- mean absolute error mHealth mobile health
- PPMC
- Pearson Product Moment Correlatio
- RR
- respiratory rate
- SD
- standard deviation
- SUS
- System Usability Scale
